ESR1 and invasive breast carcinoma: Variant PR and ER expression in BrCa could provide a mechanism for abnormal proliferation, while the loss of normal expression for these receptors could inhibit normal response to the hormones, leading to discrepancies between the reported PR/ER status of a tumor and the progression of the disease or the response to endocrine therapies.